Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

514

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine/lixisenatide fixed ratio combination
DRUG: liraglutide
DRUG: exenatide
DRUG: exenatide extended-release
DRUG: albiglutide
DRUG: dulaglutide
DRUG: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)

Sponsor

Sanofi